Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;321(1):300-334.
doi: 10.1111/imr.13274. Epub 2023 Sep 8.

Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy

Shutong Li  1 , Aoxue Wang  1 , Yongya Wu  1 , Shengyuan He  1 , Wen Shuai  1 , Min Zhao  1 , Yumeng Zhu  1 , Xiuying Hu  1 , Yubin Luo  1 , Guan Wang  1
Affiliations
Review

Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy

Shutong Li et al. Immunol Rev. 2024 Jan.

Abstract

Non-small-cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small-molecule compounds targeting various types of RCD have shown potential as anticancer treatments. Moreover, RCD appears to be a specific part of the antitumor immune response; hence, the combination of RCD and immunotherapy might increase the inhibitory effect of therapy on tumor growth. In this review, we summarize small-molecule compounds used for the treatment of NSCLC by focusing on RCD and pharmacological systems. In addition, we describe the current research status of an immunotherapy combined with an RCD-based regimen for NSCLC, providing new ideas for targeting RCD pathways in combination with immunotherapy for patients with NSCLC in the future.

Keywords: Ferroptosis; apoptosis; immunotherapy; non-small-cell lung cancer; regulated cell death.

PubMed Disclaimer

References

REFERENCES

    1. Park JE, Lee JH, Lee SY, et al. Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer. J Cancer. 2020;11(18):5503-5510.
    1. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:1031-1094.
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454.
    1. Guo W, Du K, Luo S, Hu D. Recent advances of autophagy in non-small cell lung cancer: from basic mechanisms to clinical application. Front Oncol. 2022;12:861-959.
    1. Liao M, Qin R, Huang W, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15(1):44.

Publication types

LinkOut - more resources